Low-dose methotrexate: A mainstay in the treatment of rheumatoid arthritis

Pharmacological Reviews

Volumn 57, Issue 2, 2005, Pages 163-172

  Cronstein, Bruce N ^a,b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Medicine Pathology and Pharmacology ^*  (United States)

^c Division of Clinical Pharmacology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ADENOSINE RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINIC ACID; GLUTATHIONE; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; SPERMIDINE; SPERMINE; TUMOR NECROSIS FACTOR ANTIBODY;

ALOPECIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; GENETIC PREDISPOSITION; GLUTATHIONE METABOLISM; HUMAN; INTERSTITIAL PNEUMONIA; LIVER FUNCTION; LIVER TOXICITY; LOW DRUG DOSE; LUNG FIBROSIS; METHYLATION; MONOCYTE; OXIDATION REDUCTION REACTION; PHARMACOGENETICS; PRIORITY JOURNAL; PURINE METABOLISM; PYRIMIDINE METABOLISM; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; STOMATITIS; T LYMPHOCYTE;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; METHOTREXATE;

EID: 22944470530     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.57.2.3     Document Type: Review

References (142)

1. Ahern M, Booth J, Loxton A, McCarthy P, Meffin P, and Kevat S (1988) Methotrexate kinetics in rheumatoid arthritis: is there an interaction with nonsteroidal antiinflammatory drugs? J Rheumatol 15:1356-1360.
2. Alarcon GS, Tracy IC, and Blackburn WD Jr (1989) Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 32:671-676.
3. Allegra CJ, Drake JC, Jolivet J, and Chabner BA (1985) Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA 82:4881-4885.
4. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines (2002) Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 46:328-346.
5. Andersen PA, West SG, O'Dell JR, Via CS, Claypool RG, and Kotzin BL (1985) Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 103:489-496.
6. Andersson SE, Johansson LH, Lexmuller K, and Ekstrom GM (2000) Anti-arthritic effect of methotrexate: is it really mediated by adenosine? Eur J Pharm Sci 9:333-343.
7. Asako H, Wolf RE, and Granger DN (1993) Leukocyte adherence in rat mesenteric venules: effects of adenosine and methotrexate. Gastroenterology 104:31-37.
8. Baggott JE, Morgan SL, Sams WM, and Linden J (1999) Urinary adenosine and aminoimidazolecarboxamide excretion in methotrexate-treated patients with psoriasis. Arch Dermatol 135:813-817.
9. Baggott JE, Vaughn WH, and Hudson BB (1986) Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 236:193-200.
10. Bannwarth B, Pehourcq F, Schaeverbeke T, and Dehais J (1996) Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 30:194-210.
11. Barankiewicz J, Ronlov G, Jimenez R, and Gruber HE (1990) Selective adenosine release from human B but not T lymphoid cell line. J Biol Chem 265:15738-15743.
12. Bathon JM and Genovese MC (2003) The Early Rheumatoid Arthritis (ERA) trial comparing the efficacy and safety of etanercept and methotrexate. Clin Exp Rheumatol 21:S195-S197.
13. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, et al. (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343:1586-1593.
14. Baumgartner SW, Fleischmann RM, Moreland LW, Schiff MH, Markenson J, and Whitmore JB (2004) Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. J Rheumatol 31:1532-1537.
15. Bernini JC, Fort DW, Griener JC, Kane BJ, Chappell WB, and Kamen BA (1995) Aminophylline for methotrexate-induced neurotoxicity. Lancet 345:544-547.
16. Bjorkman DJ, Boschert M, Tolman KG, Clegg DO, and Ward JR (1993) The effect of long-term methotrexate therapy on hepatic fibrosis in rheumatoid arthritis. Arthritis Rheum 36:1697-1701.
17. Bologna C, Viu P, Picot MC, Jorgensen C, and Sany J (1997) Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study. Br J Rheumatol 36:535-540.
18. Brick JE, Moreland LW, Al-Kawas F, Chang WW, Layne RD, and DiBartolomeo AG (1989) Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients. Semin Arthritis Rheum 19:31-44.
19. Carmichael SJ, Beal J, Day RO, and Tett SE (2002) Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J Rheumatol 29:2077-2083.
20. Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, Drake JC, and Jolivet J (1985) Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Investig 76:907-912.
21. Cooper BA (1996) Folic acid and methotrexate in rheumatoid arthritis. Ann Intern Med 124:73; discussion 74.
22. Cronstein BN, Eberle MA, Gruber HE, and Levin RI (1991) Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci USA 88:2441-2445.
23. Cronstein BN, Naime D, and Ostad E (1993) The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Investig 92:2675-2682.
24. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, and Kremer J (2004) Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 50:2766-2774.
25. Dervieux T, Orentas Lein D, Marcelletti J, Pischel K, Smith K, Walsh M, and Richerson R (2003) HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin Chem 49:1632-1641.
26. Dijkmans BA (1995) Folate supplementation and methotrexate (Review). Br J Rheumatol 34:1172-1174.
27. Egan LJ, Sandborn WJ, Mays DC, Tremaine WJ, and Lipsky JJ (1999) Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate. Inflamm Bowel Dis 5:167-173.
28. Endresen GK and Husby G (2001) Folate supplementation during methotrexate treatment of patients with rheumatoid arthritis. An update and proposals for guidelines. Scand J Rheumatol 30:129-134.
29. Fantone JC, Duque RE, Davis BH, and Phan SH (1989) 3-Deaza-adenosine inhibition of stimulus-response coupling in human polymorphonuclear leukocytes. J Leukoc Biol 45:121-128.
30. Ferraccioli GF, Assaloni R, Di Poi E, Gremese E, De Marchi G, and Fabris M (2002) Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trial. Rheumatology (Oxford) 41:1109-1112.
31. Flescher E, Bowlin TL, Ballester A, Houk R, and Talal N (1989) Increased polyamines may downregulate interleukin 2 production in rheumatoid arthritis. J Clin Investig 83:1356-1362.
32. Flescher E, Bowlin TL, and Talal N (1992) Regulation of IL-2 production by mononuclear cells from rheumatoid arthritis synovial fluids. Clin Exp Immunol 87:435-437.
33. Fossa SD, Tveit K, Bormer O, Moxnes A, Jorgensen NP, Orjaseter H, and Kristoffersen DT (1988) Relative bioavailability of oral low dose methotrexate. A comparison of two different formulations. Eur J Clin Pharmacol 34:517-519.
34. Furst DE (1995) Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis (Review). Br J Rheumatol 34 (Suppl 2):20-25.
35. Furst DE, Erikson N, Clute L, Koehnke R, Burmeister LF, and Kohler JA (1990) Adverse experience with methotrexate during 176 weeks of a long-term prospective trial in patients with rheumatoid arthritis. J Rheumatol 17:1628-1635.
36. Furst DE, Koehnke R, Burmeister LF, Kohler J, and Cargill I (1989) Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 16:313-320.
37. Furumitsu Y, Yukioka K, Kojima A, Yukioka M, Shichikawa K, Ochi T, Matsui-Yuasa I, Otani S, Nishizawa Y, and Morii H (1993) Levels of urinary polyamines in patients with rheumatoid arthritis. J Rheumatol 20:1661-1665.
38. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, and Revillard JP (1998) Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Investig 102:322-328.
39. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver AL, et al. (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46:1443-1450.
40. Gruber HE, Hoffer ME, McAllister DR, Laikind PK, Lane TA, Schmid-Schoenbein GW, and Engler RL (1989) Increased adenosine concentration in blood from ischemic myocardium by AICA riboside: effects on flow, granulocytes and injury. Circulation 80:1400-1411.
41. Gubner R, August S, and Ginsberg V (1951) Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 221:176-182.
42. Hanrahan PS, Scrivens GA, and Russell AS (1989) Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression. Br J Rheumatol 28:147-153.
43. Hasko G and Cronstein BN (2004) Adenosine: an endogenous regulator of innate immunity. Trends Immunol 25:33-39.
44. Hawkes JS, Cleland LG, Proudman SM, and James MJ (1994) The effect of methotrexate on ex vivo lipoxygenase metabolism in neutrophils from patients with rheumatoid arthritis. J Rheumatol 21:55-58.
45. Hill RL, Topliss DJ, and Purcell PM (2003) Pancytopenia associated with leflunomide and methotrexate. Ann Pharmacother 37:149.
46. Hochberg MC, Tracy JK, Hawkins-Holt M, and Flores RH (2003) Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 62 (Suppl 2):ii13-ii16.
47. Hoffmeister RT (1983) Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am J Med 75:69-73.
48. Hunt PG, Rose CD, McIlvain-Simpson G, and Tejani S (1997) The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. A controlled study. J Rheumatol 24:2230-2232.
49. Izeradjene K, Revillard JP, and Genestier L (2001) Inhibition of thymidine synthesis by folate analogues induces a Fas-Fas ligand-independent deletion of superantigen-reactive peripheral T cells. Int Immunol 13:85-93.
50. Jeong SY, Lee JH, Kim HS, Hong SH, Cheong CH, and Kim IK (1996) 3-Deazaadenosine analogues inhibit the production of tumour necrosis factor-alpha in RAW264.7 cells stimulated with lipopolysaccharide. Immunology 89:558-562.
51. Jundt JW, Browne BA, Fiocco GP, Steele AD, and Mock D (1993) A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 20:1845-1849.
52. Jurgensen CH, Huber BE, Zimmerman TP, and Wolberg G (1990) 3-Deazaadenosine inhibits leukocyte adhesion and ICAM-1 biosynthesis in tumor necrosis factor-stimulated human endothelial cells. J Immunol 144:653-661.
53. Jurgensen CH, Wolberg G, and Zimmerman TP (1989) Inhibition of neutrophil adherence to endothelial cells by 3-deazaadenosine. Agents Actions 27:398-400.
54. Kavanaugh A and Kavanaugh D (1996) Folic acid and methotrexate in rheumatoid arthritis. Ann Intern Med 124:73; discussion 74.
55. Kevat S, Ahern M, and Hall P (1988) Hepatotoxicity of methotrexate in rheumatic diseases. Med Toxicol Adverse Drug Exp 3:197-208.
56. Kozloski GD, De Vito JM, Kisicki JC, and Johnson JB (1992) The effect of food on the absorption of methotrexate sodium tablets in healthy volunteers. Arthritis Rheum 35:761-764.
57. Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Furst DE, Luggen M, Keystone E, Bathon J, Kavanaugh A, et al. (2004) Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. J Rheumatol 31:1521-1531.
58. Kremer JM, Galivan J, Streckfuss A, and Kamen B (1986) Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 29:832-835.
59. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, Luggen ME, Keystone E, Weisman MH, Bensen WM, et al. (2002) Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:726-733.
60. Kremer JM and Hamilton RA (1995) The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J Rheumatol 22:2072-2077.
61. Kremer JM and Lee JK (1986) The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 29:822-831.
62. Kremer JM, Lee RG, and Tolman KG (1989) Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. Arthritis Rheum 32:121-127.
63. Kremer JM, Petrillo GF, and Hamilton RA (1995) Examination of pharmacokinetic variables in a cohort of patients with rheumatoid arthritis beginning therapy with methotrexate compared with a cohort receiving the drug for a mean of 81 months. J Rheumatol 22:41-44.
64. Kremer JM and Phelps CT (1992) Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum 35:138-145.
65. Krenitsky TA, Rideout JL, Chao EY, Koszalka GW, Gurney F, Crouch RC, Cohn NK, Wolberg G, and Vinegar R (1986) Imidazo[4,5-c]pyridines (3-deazapurines) and their nucleosides as immunosuppressive and antiinflammatory agents. J Med Chem 29:138-143.
66. Kumagai K, Hiyama K, Oyama T, Maeda H, and Kohno N (2003) Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 11:593-600.
67. Laghi Pasini F, Capecchi PL, and Di Perri T (1997) Adenosine plasma levels after low dose methotrexate administration. J Rheumatol 24:2492-2493.
68. Lanse SB, Arnold GL, Gowans JD, and Kaplan MM (1985) Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis and rheumatoid arthritis. An acceptable risk/benefit ratio. Dig Dis Sci 30:104-109.
69. Lebbe C, Beyeler C, Gerber NJ, and Reichen J (1994) Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. Ann Rheum Dis 53:475-477.
70. Leonard EJ, Skeel A, Chiang PK, and Cantoni GL (1978) The action of the adenosylhomocysteine hydrolase inhibitor, 3-deazaadenosine, on phagocytic function of mouse macrophages and human monocytes. Biochem Biophys Res Commun 84:102-109.
71. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594-1602.
72. Luhby AL and Cooperman JH (1962) Aminoimidazole carboxamide excretion in vitamin B12 and folic acid deficiencies. Lancet 2:1381-1382.
73. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, et al. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552-1563.
74. Matherly LH and Goldman DI (2003) Membrane transport of folates. Vitam Horm 66:403-456.
75. Maurice MM, Nakamura H, van der Voort EA, van Vliet AI, Staal FJ, Tak PP, Breedveld FC, and Verweij CL (1997) Evidence for the role of an altered redox state in hyporesponsiveness of synovial T cells in rheumatoid arthritis. J Immunol 158:1458-1465.
76. Medzihradsky JL (1984) Regulatory role for the immune complex in modulation of phagocytosis by 3-deazaadenosine. J Immunol 133:946-949.
77. Mielants H, Veys EM, Van der Straeten C, Ackerman C, and Goemaere S (1991) The efficacy and toxicity of a constant low dose of methotrexate as a treatment for intractable rheumatoid arthritis: an open prospective study. J Rheumatol 18:978-983.
78. Montesinos MC, Desai A, Delano D, Chen JF, Fink JS, Jacobson MA, and Cronstein BN (2003) Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 48:240-247.
79. Montesinos MC, Yap JS, Desai A, Posadas I, McCrary CT, and Cronstein BN (2000) Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum 43:656-663.
80. Morabito L, Montesinos MC, Schreibman DM, Balter L, Thompson LF, Resta R, Carlin G, Huie MA, and Cronstein BN (1998) Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′- nucleotidase-mediated conversion of adenine nucleotides. J Clin Investig 101:295-300.
81. Morgan S, Alarcon GS, and Krumdieck CL (1993) Folic acid supplementation during methotrexate therapy: it makes sense. J Rheumatol 20:929-930.
82. Morgan SL, Baggott JE, Lee JY, and Alarcon GS (1998) Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during long-term, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 25:441-446.
83. Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, Koopman WJ, Krumdieck CL, and Alarcon GS (1994) Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med 121:833-841.
84. Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, and Alarcon GS (1990) The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 33:9-18.
85. Mroczkowski PJ, Weinblatt ME, and Kremer JM (1999) Methotrexate and leflunomide combination therapy for patients with active rheumatoid arthritis. Clin Exp Rheumatol 17:S66-S68.
86. Nesher G, Mates M, and Zevin S (2003) Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum 48:571-572.
87. Nesher G and Moore TL (1990) The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine. Arthritis Rheum 33:954-959.
88. Nesher G, Osborn TG, and Moore TL (1996) In vitro effects of methotrexate on polyamine levels in lymphocytes from rheumatoid arthritis patients. Clin Exp Rheumatol 14:395-399.
89. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, Garwood V, Maloley P, Klassen LW, Wees S, et al. (1996) Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 334:1287-1291.
90. O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, Fernandez A, Blakely K, Wees S, Stoner J, et al. (2002) Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications. Results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:1164-1170.
91. Oguey D, Kolliker F, Gerber NJ, and Reichen J (1992) Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 35:611-614.
92. Ortiz Z, Shea B, Suarez Almazor M, Moher D, Wells G, and Tugwell P (2000) Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2:CD000951.
93. Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, and Tugwell P (1998) The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 25:36-43.
94. Paillot R, Genestier L, Fournel S, Ferraro C, Miossec P, and Revillard JP (1998) Activation-dependent lymphocyte apoptosis induced by methotrexate. Transplant Proc 30:2348-2350.
95. Phillips DC, Woollard KJ, and Griffiths HR (2003) The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br J Pharmacol 138:501-511.
96. Pincus T (1998) Folic and folinic acid supplementation reduces methotrexate gastrointestinal side effects in rheumatoid arthritis. Clin Exp Rheumatol 16:667-668.
97. Prus KL, Wolberg G, Keller PM, Fyfe JA, Stopford CR, and Zimmerman TP (1989) 3-Deazaadenosine 5′-triphosphate: a novel metabolite of 3- deazaadenosine in mouse leukocytes. Biochem Pharmacol 38:509-517.
98. Prytz S, Loennechen T, Johansson A, Larsen LB, Slordal L, and Aarbakke J (1989) Effects of 3-deazaadenosine, an inducer of HL-60 cell differentiation, on human blood cells in vitro. Pediatr Hematol Oncol 6:173-179.
99. Quemeneur L, Gerland LM, Flacher M, Ffrench M, Revillard JP, and Genestier L (2003) Differential control of cell cycle, proliferation and survival of primary T lymphocytes by purine and pyrimidine nucleotides. J Immunol 170:4986-4995.
100. Rau R, Schleusser B, Herborn G, and Karger T (1997) Long-term treatment of destructive rheumatoid arthritis with methotrexate. J Rheumatol 24:1881-1889.
101. Ravelli A, Migliavacca D, Viola S, Ruperto N, Pistorio A, and Martini A (1999) Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clin Exp Rheumatol 17:625-627.
102. Richard S, Guerret S, Gerard F, Tebib JG, and Vignon E (2000) Hepatic fibrosis in rheumatoid arthritis patients treated with methotrexate: application of a new semi-quantitative scoring system. Rheumatology (Oxford) 39:50-54.
103. Ruderman EM, Crawford JM, Maier A, Liu JJ, Gravallese EM, and Weinblatt ME (1997) Histologic liver abnormalities in an autopsy series of patients with rheumatoid arthritis. Br J Rheumatol 36:210-213.
104. Sany J, Anaya JM, Lussiez V, Couret M, Combe B, and Daures JP (1991) Treatment of rheumatoid arthritis with methotrexate: a prospective open long-term study of 191 cases. J Rheumatol 18:1323-1327.
105. Schroder O, Blumenstein I, Schulte-Bockholt A, and Stein J (2004) Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine. Aliment Pharmacol Ther 19:295-301.
106. Shergy WJ, Polisson RP, Caldwell DS, Rice JR, Pisetsky DS, and Allen NB (1988) Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. Am J Med 85:771-774.
107. Shiroky JB (1996) Folic acid and methotrexate in rheumatoid arthritis. Ann Intern Med 124:73-74.
108. Shiroky JB (1997) The use of folates concomitantly with low-dose pulse methotrexate. Rheum Dis Clin N Am 23:969-980.
109. Silke C, Murphy MS, Buckley T, Busteed S, Molloy MG, and Phelan M (2001) The effects of caffeine ingestion on the efficacy of methotrexate. Rheumatology (Oxford) 40 (Suppl 1):34.
110. Smith DM, Johnson JA, and Turner RA (1991) Biochemical perturbations of BW 91Y (3-deazaadenosine) on human neutrophil chemotactic potential and lipid metabolism. Int J Tissue React 13:1-18.
111. Smolenska Z, Kaznowska Z, Zarowny D, Simmonds HA, and Smolenski RT (1999) Effect of methotrexate on blood purine and pyrimidine levels in patients with rheumatoid arthritis. Rheumatology (Oxford) 38:997-1002.
112. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, et al. (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50:3432-3443.
113. Stewart CF, Fleming RA, Arkin CR, and Evans WE (1990) Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. Clin Pharmacol Ther 47:540-546.
114. Stewart CF, Fleming RA, Germain BF, Seleznick MJ, and Evans WE (1991) Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis Rheum 34:1514-1520.
115. Sung JY, Hong JH, Kang HS, Choi I, Lim SD, Lee JK, Seok JH, Lee JH, and Hur GM (2000) Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis. Immunopharmacology 47:35-44.
116. Sung SSJ and Silverstein SC (1985) Inhibition of macrophage phagocytosis by methylation inhibitors: lack of correlation of protein carboxymethylation and phospholipid methylation with phagocytosis. J Biol Chem 260:546-554.
117. Talal N, Tovar Z, Dauphinee MJ, Flescher E, Dang H, and Galarza D (1988) Abnormalities of T cell activation in the rheumatoid synovium detected with monoclonal antibodies to CD3. Scand J Rheumatol Suppl 76:175-182.
118. Thompson RN, Watts C, Edelman J, Esdaile J, and Russell AS (1984) A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol 11:760-763.
119. Tishler M, Caspi D, Fishel B, and Yaron M (1988) The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis Rheum 31:906-908.
120. Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, and Brater DC (1992) The effects of a salicylate, ibuprofen and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol 42:121-125.
121. Tracy TS, Worster T, Bradley JD, Greene PK, and Brater DC (1994) Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. Br J Clin Pharmacol 37:453-456.
122. Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y, Akama H, Kitamura Y, and Kamatani N (2002) Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12:183-190.
123. van Ede AE, Laan RF, Blom HJ, Huizinga TW, Haagsma CJ, Giesendorf BA, de Boo TM, and van de Putte LB (2001a) The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 44:2525-2530.
124. van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, Westgeest TA, Romme TC, de Rooij DJ, Jacobs MJ, et al. (2001b) Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 44:1515-1524.
125. Vincent MF, Bontemps F, and Van den Berghe G (1996) Substrate cycling between 5-amino-4-imidazolecarboxamide riboside and its monophosphate in isolated rat hepatocytes. Biochem Pharmacol 52:999-1006.
126. Weinblatt ME (1989) Drug interactions with non steroidal anti-inflammatory drugs (NSAIDs). Scand J Rheumatol Suppl 83:7-10.
127. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, and Trentham DE (1985) Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312:818-822.
128. Weinblatt ME, Dixon JA, and Falchuk KR (2000) Serious liver disease in a patient receiving methotrexate and leflunomide. Arthritis Rheum 43:2609-2611.
129. Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, Wolfe F, Wall B, Anderson L, Gall E, et al. (1994) Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 37:1492-1498.
130. Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, Byrne VM, Kaymakcian MV, and Strand V (1999) Pharmacokinetics, safety and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 42:1322-1328.
131. Weinblatt ME, Maier AL, Fraser PA, and Coblyn JS (1998) Long-term prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol 25:238-242.
132. Weinblatt ME, Trentham DE, Fraser PA, Holdsworth DE, Falchuk KR, Weissman BN, and Coblyn JS (1988) Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 31:167-175.
133. Weinblatt ME, Weissman BN, Holdsworth DE, Fraser PA, Maier AL, Falchuk KR, and Coblyn JS (1992) Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-Month update. Arthritis Rheum 35:129-137.
134. Weinstein A, Marlowe S, Korn J, and Farouhar F (1985) Low-dose methotrexate treatment of rheumatoid arthritis. Long-term observations. Am J Med 79:331-337.
135. Whiting-O'Keefe QE, Fye KH, and Sack KD (1991) Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 90:711-716.
136. Wilke WS, Calabrese LH, and Scherbel AL (1980) Methotrexate in the treatment of rheumatoid arthritis; pilot study. Cleve Clin Q 47:305-339.
137. Williams HJ, Willkens RF, Samuelson CO Jr, Alarcon GS, Guttadauria M, Yarboro C, Polisson RP, Weiner SR, Luggen ME, Billingsley LM, et al. (1985) Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 28:721-730.
138. Willkens RF (1985) Methotrexate treatment of rheumatoid arthritis. Ann Intern Med 103:612-613.
139. Willkens RF, Watson MA, and Paxson CS (1980) Low dose pulse methotrexate therapy in rheumatoid arthritis. J Rheumatol 7:501-505.
140. Yagawa K, Nakanishi M, Hayashi S, Kaku M, Ichinose Y, Itoh T, Tomoda A, Yoneyama Y, and Shigematsu N (1986) Abolishment of inhibitory effects of 3′-deazaadenosine on superoxide generation of guinea pig phagocytes by pre-exposure to phorbol myristate acetate. FEBS Lett 201:287-290.
141. Yukioka K, Wakitani S, Yukioka M, Furumitsu Y, Shichikawa K, Ochi T, Goto H, Matsui-Yuasa I, Otani S, Nishizawa Y, et al. (1992) Polyamine levels in synovial tissues and synovial fluids of patients with rheumatoid arthritis. J Rheumatol 19:689-692.
142. Zimmerman TP, Wolberg G, and Duncan GS (1978) Inhibition of lymphocyte-mediated cytolysis by 3-deazaadenosine: evidence for a methylation reaction essential for cytolysis. Proc Natl Acad Sci USA 75:6220-6224.